A study to evaluate impact of Digital inhaler on asthma control

Digital pMDIs in Asthma: Drug Utilization Surveillance (DUS) study - DUSS

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2018/06/014595

Enrollment

5000

Registered

2018-06-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Bronchial Asthma Health Condition 2: J455- Severe persistent asthma

Interventions

Intervention1: Digihaler SF 25/125 or Digihaler FB 6/200: Twice daily for 8 weeks Control Intervention1: NA: NA

Eligibility

Inclusion criteria

Inclusion criteria: Bronchial asthma cases on Digital dose-counter pMDIs

Exclusion criteria

Exclusion criteria: Patient records without baseline symptom evaluation based on GINA assessment questionnaire

Design outcomes

Primary

Measure	Time frame
Asthma control statusTimepoint: 8 weeks	—

Secondary

Measure	Time frame
Subjective assessment of patientsâ?? acceptability of deviceTimepoint: 8 weeks	—

Countries

India

Contacts

Public ContactDr K Krishnaprasad

Glenmark Pharmaceuticals Ltd.

K.Krishna.Prasad@glenmarkpharma.com9820806811

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 21, 2026